Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease

Inflammatory Bowel Disease

Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial

Inflamm Bowel Dis.

Gawronska A, Banasiuk M, Lachowicz D, Pituch H, Albrecht P, Banaszkiewicz A

doi: 10.1097/

Inflammatory Bowel Disease

Lasting Impact of Clostridium difficile Infection in Inflammatory Bowel Disease: A Propensity Score Matched Analysis

Inflamm Bowel Dis.

Anderson A, Click B, Ramos-Rivers C, Cheng D, Babichenko D, Koutroubakis IE, Hashash JG, Schwartz M, Swoger J, Barrie AM 3rd, Dunn MA, Regueiro M, Binion DG

doi: 10.1097/

Gastrointestinal Cancer

Fecal Microbiota Transplantation: Current Status in Treatment of GI and Liver Disease

Clin Gastroenterol Hepatol.

Vaughn BP, Rank KM, Khoruts A

doi: 10.1016/j.cgh.2018.07.026.

Inflammatory Bowel Disease

Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

Eur J Clin Microbiol Infect Dis.

Vehreschild MJGT, Taori S, Goldenberg SD, Thalhammer F, Bouza E, van Oene J, Wetherill G, Georgopali A

doi: 10.1007/s10096-018-3344-1.

Inflammatory Bowel Disease

Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: a Systematic Review

Gastroenterology.

Pittayanon R, Lau JT, Leontiadis GI, Tse F, Yuan Y, Surette M, Moayyedi P

doi: 10.1053/j.gastro.2019.11.294.

Inflammatory Bowel Disease

Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activation and Self-Efficacy

Dig Dis Sci.

Bilgrami Z, Abutaleb A, Chudy-Onwugaje K, Langenberg P, Regueiro M, Schwartz DA, Tracy JK, Ghazi L, Patil SA, Quezada SM, Russman KM, Quinn CC, Jambaulikar G, Beaulieu DB, Horst S, Cross RK Jr

doi: 10.1007/s10620-018-

Inflammatory Bowel Disease

Clinical and Fecal Microbial Changes With Diet Therapy in Active Inflammatory Bowel Disease

J Clin Gastroenterol.

Suskind DL, Cohen SA, Brittnacher MJ, Wahbeh G, Lee D, Shaffer ML, Braly K, Hayden HS, Klein J, Gold B, Giefer M, Stallworth A, Miller SI

doi: 10.1097/

Inflammatory Bowel Disease

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

United European Gastroenterol J.

Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A

doi: 10.1177/2050640620929133.

Inflammatory Bowel Disease

Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease

United European Gastroenterol J.

Schreiner P, Yilmaz B, Rossel JB, Franc Y, Misselwitz B, Scharl M, Zeitz J, Frei P, Greuter T, Vavricka SR, Pittet V, Siebenhüner A, Juillerat P, von Känel R, Macpherson AJ, Rogler G, Biedermann L, Swiss IBD Cohort Study Group.

doi: 10.1177/2050640619841249.

Related content

Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial

Lasting Impact of Clostridium difficile Infection in Inflammatory Bowel Disease: A Propensity Score Matched Analysis

Fecal Microbiota Transplantation: Current Status in Treatment of GI and Liver Disease

Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: a Systematic Review

Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activation and Self-Efficacy

Clinical and Fecal Microbial Changes With Diet Therapy in Active Inflammatory Bowel Disease

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease